Spinal Cord Injury: A Review of Current Therapy, Future Treatments, and Basic Science Frontiers

Varma, Abhay; Das, Arabinda; Wallace, Gerald; Barry, John; Vertegel, Alexey; Ray, Swapan; Banik, Naren
May 2013
Neurochemical Research;May2013, Vol. 38 Issue 5, p895
Academic Journal
The incidence of acute and chronic spinal cord injury (SCI) in the United States is more than 10,000 per year, resulting in 720 cases per million persons enduring permanent disability each year. The economic impact of SCI is estimated to be more than 4 billion dollars annually. Preclinical studies, case reports, and small clinical trials suggest that early treatment may improve neurological recovery. To date, no proven therapeutic modality exists that has demonstrated a positive effect on neurological outcome. Emerging data from recent preclinical and clinical studies offer hope for this devastating condition. This review gives an overview of current basic research and clinical studies for the treatment of SCI.


Related Articles

  • Stem cells: A time to heal. Willyard, Cassandra // Nature;11/14/2013 Supplement, Vol. 503 Issue 7475, pS4 

    The article focuses on the clinical trials of stem-cell therapies for the treatment of spinal cord injuries. It discusses the case of Katie Sharify, a 23-year-old student at the University of Southern California, who agreed to participate in a clinical trial of a therapy using embryonic stem...

  • A Multi-disciplinary Approach to Spinal Cord Injuries Most Likely To Achieve Results.  // O&P Business News;5/1/2010, Vol. 19 Issue 6, p40 

    The article reports on a study about the likely occurrence of a multi-disciplinary approach to spinal cord injuries (SCI). It mentions that new therapeutic approaches, including stem cell therapy and novel drug formulation, would likely be used in managing SCI patients. It states that clinical...

  • Confirming an experimental therapy prior to transfer to humans: What is the ideal? Dietrich, W. Dalton // Journal of Rehabilitation Research & Development;Jul/Aug2003, Vol. 40 Issue 4, p63 

    Discusses several factors that must be considered in moving neuroprotective or regenerative treatments for spinal cord injury (SCI) to clinical trials. Information on animal models of SCI; Significance of safety issues in transplantation studies; Problems with the design of clinical trials.

  • Biotech reaches Phase 3 with drug. Prezioso, Jeanine // Westchester County Business Journal;7/22/2002, Vol. 41 Issue 29, p5 

    Reports on the phase three clinical trial for Fampridine, a drug for spinal cord-injured patients from biotechnology company Acorda Therapeutics. Volume of patients suffering from spinal cord injuries in the U.S.; Discussion of the research conducted on neurological disorders; Efficacy of the drug.

  • Methylprednisolone for acute spinal cord injury: not a standard of care. Hugenholtz, Herman // CMAJ: Canadian Medical Association Journal;4/29/2003, Vol. 168 Issue 9, p1145 

    Reports the conclusion of a committee of Canadian neurosurgical and orthopedic spine specialists and physicians that high-dose methylprednisolone infusion is not an evidence-based standard of care for patients with acute spinal cord injury. Discussion of three clinical trials, the National...

  • Cellular therapies for spinal cord injury: What will the FDA need to approve moving from the laboratory to the human? Sagen, Jacqueline // Journal of Rehabilitation Research & Development;Jul/Aug2003, Vol. 40 Issue 4, p71 

    Presents an overview of U.S. Food and Drug Administration guidelines relevant to moving cellular transplantation therapies for spinal cord injury to clinical trials. Advantages and disadvantages of cell implantation at central or peripheral sites; Functions of the U.S. Center for Biologics...

  • Cellular therapies for treating pain associated with spinal cord injury.  // Journal of Translational Medicine;2012, Vol. 10 Issue 1, p37 

    The article presents information on the use and effectiveness of cell-based or cell-related therapies for the treatment of pain associated with spinal cord injuries (SCI). SCI are generally caused by falls, motor vehicle accidents, community violence, sports injury and work-related injuries....

  • The Therapeutic Profile of Rolipram, PDE Target and Mechanism of Action as a Neuroprotectant following Spinal Cord Injury. Schaal, Sandra Marie; Garg, Maneesh Sen; Ghosh, Mousumi; Lovera, Lilie; Lopez, Michael; Patel, Monal; Louro, Jack; Patel, Samik; Tuesta, Luis; Wai-Man Chan; Pearse, Damien Daniel; Ceña, Valentin // PLoS ONE;Sep2012, Vol. 7 Issue 9, Special section p1 

    The extent of damage following spinal cord injury (SCI) can be reduced by various neuroprotective regimens that include maintaining levels of cyclic adenosine monophosphate (cyclic AMP), via administration of the phosphodiesterase 4 (PDE4) inhibitor Rolipram. The current study sought to...

  • Head and Spinal Cord Injuries: A Pilot Study of Morbidity Survey Procedures. Kalsbeek, William D.; Hartwell, Tyler D. // American Journal of Public Health;Nov77, Vol. 67 Issue 11, p1051 

    This paper describes a pilot case-finding survey which allowed statistical resolution of a number of methodological issues facing researchers who conduct such surveys. The pilot study for a national survey assessing the incidence, prevalence, and economic impact of head and spinal cord injuries,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics